Cargando…
Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait
Background. Multiple sclerosis (MS) therapeutics entered a new era after the development of anti-JC virus (anti-JCV) antibody assay that assesses the risk of development of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab. Objective. To determine the prevalence o...
Autores principales: | Lamdhade, S., Ashkanani, A., Alroughani, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920602/ https://www.ncbi.nlm.nih.gov/pubmed/24587917 http://dx.doi.org/10.1155/2014/861091 |
Ejemplares similares
-
Prevalence of Anti-JC Virus (JCV) Antibodies in the Multiple Sclerosis (MS) Population in Cyprus: A Retrospective Study
por: Lambrianides, Sakis, et al.
Publicado: (2019) -
Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria
por: Alroughani, R., et al.
Publicado: (2012) -
Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013) -
JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
por: Mancuso, Roberta, et al.
Publicado: (2012) -
Economic burden of multiple sclerosis on Kuwait health care system
por: Alowayesh, Maryam S., et al.
Publicado: (2019)